ViOL Selects Actress Kim Shin-rok as First Official Model for SYLFIRM X

- The Icon of Intellectual Beauty, Kim Shin-rok, Meets Cutting-Edge Technology: Accelerating Expansion in the Premium Aesthetic Medical Device Market
- Strengthening the Brand Message of "Restoring the Skin's Natural Beauty" with the Precision of 0.3mm Microneedle Radiofrequency

ViOL Co., Ltd, a company specializing in aesthetic medical devices, has selected actress Kim Shin-rok as the first official model for its innovative microneedle radiofrequency device, SYLFIRM X.

ViOL explained that the image of Kim Shin-rok, who embodies both intellectual and smart beauty as well as healthy skin, perfectly aligns with the brand philosophy of SYLFIRM X, which is to pursue fundamental skin improvement through smart technology.

Actress Kim Shin-rok has earned the public's trust with her delicate and profound acting in numerous works. Recently, in the drama "Your Taste," she drew particular attention for her clear and resilient skin, presenting a healthy and vibrant image. ViOL expects that Kim Shin-rok's positive and trustworthy image will effectively convey the message of SYLFIRM X, which aims to "restore the skin's natural beauty."

SYLFIRM X is the world's first dual-wave radiofrequency microneedling device that combines multi-pulsed RF technology with a microneedling system. It features both a pulsed-wave RF (PW) mode, specialized for pigmentation and vascular lesions such as melasma and redness, and a continuous-wave RF (CW) mode, which is effective for skin regeneration, lifting, tightening, and scar improvement. This enables the device to provide customized solutions for a wide range of skin concerns.

In particular, the device allows for precise needle depth adjustment from 0.3mm to 4.0mm, and its treatment targets the papillary dermis at a depth of 300μm within the skin, effectively inducing the reinforcement of the basement membrane and the generation of Type III collagen, both of which play a key role in skin health and elasticity. Additionally, by minimizing epidermal damage, the device reduces pain and shortens recovery time, thereby enhancing both the safety of the procedure and patient satisfaction.

SYLFIRM X has demonstrated its efficacy and safety through more than 27 domestic and international clinical studies and publications. In particular, research analyzing the long-term maintenance effect of melasma treatment was published in the 2024 SCI-grade international journal "Scientific Reports," further establishing its scientific credibility. Recently, the device also received approval from the Taiwan Food and Drug Administration (TFDA) for indications including melasma, fine wrinkles, acne, and acne scar improvement, rapidly expanding its presence in the Asian market.

A ViOL representative stated, "We expect that the intellectual and healthy beauty of actress Kim Shin-rok will create a powerful synergy in delivering the advanced technology and premium brand value of SYLFIRM X," adding, "With this new model selection, we plan to further strengthen our brand message and solidify ViOL's position in the global premium aesthetic medical device market."

Meanwhile, ViOL, established in 2009, has grown based on its corporate philosophy of "developing new technologies that can benefit the world and contributing to a better life," as reflected in its name, "Victory of Life." The company has developed radiofrequency skin aesthetic devices utilizing its proprietary microneedle technology and continues to expand its product portfolio, including SYLFIRM X, Scarlett, Cellinew, and DUOTIGHT. Currently, ViOL has obtained medical device approvals in over 20 countries, including the US Food and Drug Administration (FDA), Korea Ministry of Food and Drug Safety (MFDS), European CE-MDD, Australia (TGA), Brazil (ANVISA), and China (NMPA). The company exports its products to more than 70 countries, including the United States, United Kingdom, China, and Japan, further strengthening its presence in the global market.

This content was produced with the assistance of AI translation services.